News
FDA asks Novavax for post-marketing data pledge amid stalled COVID shot review
On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and Research (CBER)—who resigned in March—warned that the mass downsizing at the agency could hamstring the regulator’s ability to review drugs beginning in 2026 or 2027.
Following massive layoffs and cuts at the FDA, Makary’s plan for the agency is yet to fully unfold. But he has hinted at what ...
Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.
Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...
New York Magazine on MSN3d
What It’s Like to Be a Vaccine Researcher in RFK Jr.’s AmericaHe is the head of HHS, and yet he continues to spout untested, unproven therapies and has only given a very lukewarm ...
The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...
Former Food and Drug Administration vaccine chief Dr. Peter Marks weighed in on Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s remarks about finding a cause of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback